Tina Marriott Larson Sells 8,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Tina Marriott Larson Sells 8,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, January 26th. The shares were sold at an average price of $8.07, for a total transaction of $64,560.00. Following the sale, the chief operating officer now owns 203,654 shares of the company's stock, valued at $1,643,487.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
递归制药公司(纳斯达克代码：RXRX-GET评级)首席运营官蒂娜·万豪·拉森在1月26日星期四的一笔交易中出售了8,000股递归制药公司的股票。这些股票以8.07美元的平均价格出售，总成交金额为64,560.00美元。出售后，首席运营官现在拥有203,654股公司股票，价值1,643,487.78美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过此超链接.
Tina Marriott Larson also recently made the following trade(s):
蒂娜·万豪·拉尔森最近还进行了以下交易：
- On Thursday, December 29th, Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.70, for a total transaction of $61,600.00.
- On Thursday, November 17th, Tina Marriott Larson sold 16,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.96, for a total transaction of $175,360.00.
- 12月29日，星期四，蒂娜·万豪·拉尔森出售了8000股递归制药公司的股票。这些股票以7.70美元的平均价格出售，总成交额为61,600.00美元。
- 11月17日，星期四，蒂娜·万豪·拉尔森出售了1.6万股递归制药公司的股票。这些股票以10.96美元的平均价格出售，总成交金额为175,360.00美元。
Recursion Pharmaceuticals Stock Up 4.3 %
递归制药类股上涨4.3%
Shares of NASDAQ RXRX opened at $8.54 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.92 and a 52 week high of $14.18. The firm's fifty day moving average is $8.41 and its 200 day moving average is $9.77.
上周五，纳斯达克RXRX的股价开盘报8.54美元。Recursion PharmPharmticals，Inc.的52周低点为4.92美元，52周高位为14.18美元。该公司的50日移动均线切入位为8.41美元，200日移动均线切入位为9.77美元。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of brokerages have recently weighed in on RXRX. SVB Leerink lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Monday, January 23rd. The Goldman Sachs Group boosted their price objective on shares of Recursion Pharmaceuticals from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Wednesday, November 9th.
最近，许多券商都加入了RXRX的行列。SVB Leerink在1月23日周一的一份报告中将其对Recursion PharmPharmticals的股票目标价从9.00美元下调至8.00美元，并为该公司设定了“市场表现”评级。在11月9日星期三的一份报告中，高盛夫妇将递归制药的股票目标价从8.00美元上调至9.00美元，并给予该股“中性”评级。
Institutional Inflows and Outflows
机构资金流入和流出
Several hedge funds have recently made changes to their positions in the company. Baillie Gifford & Co. increased its stake in shares of Recursion Pharmaceuticals by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 24,820,850 shares of the company's stock worth $191,369,000 after buying an additional 3,226,157 shares during the period. Bank of New York Mellon Corp increased its position in Recursion Pharmaceuticals by 26.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 503,941 shares of the company's stock valued at $5,362,000 after purchasing an additional 104,588 shares during the period. Teachers Retirement System of The State of Kentucky purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at $1,750,000. Advisory Research Inc. increased its position in Recursion Pharmaceuticals by 56.6% during the 3rd quarter. Advisory Research Inc. now owns 96,803 shares of the company's stock valued at $1,030,000 after purchasing an additional 34,999 shares during the period. Finally, BNP Paribas Arbitrage SNC purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at $1,139,000. 63.62% of the stock is owned by hedge funds and other institutional investors.
几家对冲基金最近对他们在该公司的头寸进行了调整。Baillie Gifford&Co.在第四季度增持了Recursion PharmPharmticals的股份14.9%。Baillie Gifford&Co.现在持有24,820,850股该公司股票，价值191,369,000美元，在此期间又购买了3,226,157股。纽约梅隆银行(Bank Of New York Mellon Corp)第三季度将其在Recursion PharmPharmticals的头寸增加了26.2%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有503,941股该公司股票，价值5,362,000美元，在此期间又购买了104,588股。肯塔基州教师退休系统在第三季度购买了一个新的递归制药职位，价值1,750,000美元。咨询研究公司在第三季度将其在递归制药公司的头寸增加了56.6%。Consulting Research Inc.在此期间又购买了34,999股，目前持有该公司96,803股股票，价值1,030,000美元。最后，法国巴黎银行套利SNC在第三季度购买了Recursion PharmPharmticals的新头寸，价值1,139,000美元。63.62%的股票由对冲基金和其他机构投资者持有。
About Recursion Pharmaceuticals
关于递归制药公司
(Get Rating)
(获取评级)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
递归制药公司是一家临床阶段的生物技术公司，通过整合跨越生物、化学、自动化、数据科学和工程的技术创新来实现药物发现的工业化，致力于解码生物学。该公司开发了REC-994，用于治疗脑海绵状血管畸形的第二阶段临床试验；REC-2282，用于治疗2型神经纤维瘤病；REC-4881，用于治疗家族性腺瘤性息肉病；以及REC-3599，用于治疗GM2神经节苷脂增多症，处于第一阶段临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取StockNews.com关于递归制药的研究报告(RXRX)
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《递归药物日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Recursion PharmPharmticals和相关公司的最新新闻和分析师评级的每日摘要。